Levetiracetam Tablet, Film Coated
Product Images NDC 55154-3367

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 55154-3367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Bag Label (0348fec4 D919 4307 Ac90 35360819bc00 00)

Bag Label (0348fec4 D919 4307 Ac90 35360819bc00 00)
Levetiracetam Tablets USP is a prescription medication used to treat seizures in adults and children. Each film-coated tablet contains 500 mg of Levetiracetam USP. Dosage recommendations, prescribing information, precautions, and warnings can be found in the product insert. These tablets should be stored at room temperature, and should be kept out of reach of children in a tight, light-resistant container with a child-resistant closure. This particular package is intended for institutional use only and should be dispensed by a pharmacist with a medication guide. The medication is distributed in the United States by Aurobindo Pharma USA, Inc and Major® Pharmaceuticals through Cardinal Health.*
FDA Label Image

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)

Figure 1: Responder Rate (≥50% Reduction From Baseline) In Study 1 (Levetiracetam Fig1)
FDA Label Image

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)

Figure 2: Responder Rate (≥50% Reduction From Baseline) In Study 2: Period A (Levetiracetam Fig2)
The image shows the Responder Rate in Study 2 where the percentage reduction from baseline is 250% during Period A. Three groups are compared, the placebo group with 111 patients, and two groups taking different doses of Levetiracetam (1000 mg/day and 2000 mg/day) with 106 and 105 patients respectively. One group had a statistically significant difference when compared to the placebo group.*
FDA Label Image

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)

Figure 3: Responder Rate (≥50% Reduction From Baseline) In Study 3 (Levetiracetam Fig3)
This is a graph depicting the responder rate of participants who experienced a reduction of over 50% in symptoms from their baseline in Study 3. The percentages are displayed on the y-axis, while the different treatment groups are shown on the x-axis. The placebo group had a responder rate of 14.4%, while the group treated with Levetiracetam 3000 mg/day had a responder rate of 45%, which was statistically significant compared to the placebo group.*
FDA Label Image

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)

Figure 4: Responder Rate (≥ 50% Reduction From Baseline) In Study 4 (Levetiracetam Fig4)
The text describes a figure (Figure 4) that shows the Responder Rate in a study (Study 4). The Responder Rate is defined as a 50% reduction from the baseline. The figure shows that the Responder Rate for Levetiracetam (N=101) is statistically significant compared to Placebo (N=97). The Responder Rate for Levetiracetam is 44.6% while for Placebo it is only 19.6%. The figure also displays a graph with percentages ranging from 40% to 30% with both Placebo and Levetiracetam marked on it.*
FDA Label Image

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)

Figure 5: Responder Rate For All Patients Ages 1 Month To < 4 Years (≥ 50% Reduction From Baseline) In Study 5 (Levetiracetam Fig5)
The figure displays the responder rate for patients aged 1 month to less than 4 years old in Study 5. The rate of reduction from baseline is greater than 50%. The response rate for Lovetracatam (4-58) is statistically significant when compared to the placebo treatment.*
FDA Label Image

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)

Figure 6: Responder Rate (≥50% Reduction From Baseline) In Pgtc Seizure Frequency Per Week In Study 7 (Levetiracetam Fig6)
The text describes a Figure 6 that shows the Responder Rate in PGTC Seizure Frequency per Week in Study 7. There is a chart with percentage values from 0% to 100%, where the Levetiracetam group had a responder rate of 72.2% compared to the placebo group which had a responder rate of 45.2%. The chart also notes that the difference between the two groups is statistically significant.*
FDA Label Image

Chemical Structure (Levetiracetam Str)

Chemical Structure (Levetiracetam Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.